Maze Therapeutics (NASDAQ:MAZE) Rating Increased to Hold at Wall Street Zen

Maze Therapeutics (NASDAQ:MAZE) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Sunday.

A number of other research firms also recently weighed in on MAZE. Weiss Ratings restated a “sell (d)” rating on shares of Maze Therapeutics in a research report on Thursday. Guggenheim reissued a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a research note on Friday, December 19th. Raymond James Financial initiated coverage on shares of Maze Therapeutics in a research note on Thursday, November 13th. They issued an “outperform” rating and a $48.00 price objective for the company. BTIG Research increased their target price on shares of Maze Therapeutics from $37.00 to $46.00 and gave the company a “buy” rating in a report on Friday, January 16th. Finally, Wells Fargo & Company began coverage on shares of Maze Therapeutics in a research note on Thursday, December 4th. They issued an “overweight” rating and a $55.00 price target for the company. Three equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Maze Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $44.50.

Maze Therapeutics Stock Performance

Shares of NASDAQ:MAZE opened at $44.27 on Friday. The firm has a market capitalization of $2.13 billion and a PE ratio of -2.12. Maze Therapeutics has a 52-week low of $6.71 and a 52-week high of $47.36. The firm has a fifty day moving average of $39.90 and a 200 day moving average of $28.06.

Maze Therapeutics (NASDAQ:MAZE) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.08.

Insider Buying and Selling at Maze Therapeutics

In other Maze Therapeutics news, SVP Amy Bachrodt sold 5,000 shares of the firm’s stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $39.15, for a total value of $195,750.00. Following the sale, the senior vice president owned 12,965 shares of the company’s stock, valued at $507,579.75. This trade represents a 27.83% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Atul Dandekar sold 72,400 shares of the business’s stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $40.56, for a total transaction of $2,936,544.00. Following the completion of the transaction, the insider owned 10,503 shares in the company, valued at $426,001.68. The trade was a 87.33% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 167,500 shares of company stock valued at $6,774,667 in the last quarter.

Hedge Funds Weigh In On Maze Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Maze Therapeutics in the first quarter worth $57,000. Goldman Sachs Group Inc. bought a new position in Maze Therapeutics in the 1st quarter worth $145,000. Rhumbline Advisers purchased a new stake in shares of Maze Therapeutics in the 1st quarter worth about $80,000. CWM LLC bought a new stake in shares of Maze Therapeutics during the 2nd quarter valued at about $28,000. Finally, Geode Capital Management LLC increased its position in shares of Maze Therapeutics by 8.8% during the second quarter. Geode Capital Management LLC now owns 231,237 shares of the company’s stock valued at $2,838,000 after buying an additional 18,773 shares during the period.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.